Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1974 Oct;37(10):1116–1120. doi: 10.1136/jnnp.37.10.1116

Buccal absorption of ergotamine

J M Sutherland 1, W D Hooper 1, M J Eadie 1, J H Tyrer 1
PMCID: PMC494854  PMID: 4443807

Abstract

The rate of disappearance of ergotamine from the mouth after buccal administration has been studied in seven subjects. Allowance has been made for non-absorptive losses of the drug due to experimental technique. The absorption of ergotamine across the buccal mucosa appears to be a passive process, pH-dependent but independent of ergotamine concentration or the simultaneous presence of caffeine. Because of the low solubility of ergotamine at the pH of saliva, it is unlikely that therapeutically useful amounts of the drug would have absorbed across the buccal mucosa even after the drug had been in the mouth for five minutes.

Full text

PDF
1116

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beckett A. H., Moffat A. C. The influence of alkyl substitution in acids on their performance in the buccal absorption test. J Pharm Pharmacol. 1968 Dec;20(Suppl):239S+–239S+. doi: 10.1111/j.2042-7158.1968.tb09889.x. [DOI] [PubMed] [Google Scholar]
  2. Bercel N. A. TREATMENT OF MIGRAINE-Results with Dihydroergocornine Methanesulfonate (DHO-180) and Other Ergot Derivatives. Calif Med. 1950 Apr;72(4):234–238. [PMC free article] [PubMed] [Google Scholar]
  3. COHEN S. G., CRIEP L. H. Observations on the symptomatic treatment of chronic vascular headache with cafergone (ergotamine tartrate and caffeine). N Engl J Med. 1949 Dec 8;241(23):896–900. doi: 10.1056/NEJM194912082412303. [DOI] [PubMed] [Google Scholar]
  4. CROOKS J., STEPHEN S. A., BRASS W. CLINICAL TRIAL OF INHALED ERGOTAMINE TARTRATE IN MIGRAINE. Br Med J. 1964 Jan 25;1(5377):221–224. doi: 10.1136/bmj.1.5377.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. FRIEDMAN A. P., VON STORCH T. J. C. Recent advances in treatment of migraine. J Am Med Assoc. 1951 Apr 28;145(17):1325–1328. doi: 10.1001/jama.1951.02920350019004. [DOI] [PubMed] [Google Scholar]
  6. GIBALDI M., KANIG J. L. ABSORPTION OF DRUGS THROUGH THE ORAL MUCOSA. J Oral Ther Pharmacol. 1965 Jan;1:440–450. [PubMed] [Google Scholar]
  7. GRAHAM J. R., MALVEA B. P., GRAMM H. F. Aerosol ergotamine tartrate for migraine and Horton's syndrome. N Engl J Med. 1960 Oct 20;263:802–804. doi: 10.1056/NEJM196010202631609. [DOI] [PubMed] [Google Scholar]
  8. GRAHAM J. R. Rectal use of ergotamine tartrate and caffeine alkaloid for the relief of migraine. N Engl J Med. 1954 Jun 3;250(22):936–938. doi: 10.1056/NEJM195406032502203. [DOI] [PubMed] [Google Scholar]
  9. Hooper W. D., Sutherland J. M., Eadie M. J., Tyrer J. H. Fluorimetric assay of ergotamine. Anal Chim Acta. 1974 Mar;69(1):11–17. doi: 10.1016/0003-2670(74)80002-4. [DOI] [PubMed] [Google Scholar]
  10. Maulding H. V., Zoglio M. A. Physical chemistry of ergot alkaloids and derivatives. I. Ionization constants of several medicinally active bases. J Pharm Sci. 1970 May;59(5):700–701. doi: 10.1002/jps.2600590526. [DOI] [PubMed] [Google Scholar]
  11. SUTHERLAND J. M., EADIE M. J. The drug therapy of migraine. Med J Aust. 1961 Nov 4;48(2):740–742. doi: 10.5694/j.1326-5377.1961.tb69979.x. [DOI] [PubMed] [Google Scholar]
  12. Zoglio M. A., Maulding H. V., Jr, Windheuser J. J. Complexes of ergot alkaloids and derivatives. I. The interaction of caffeine with ergotamine tartrate in aqueous solution. J Pharm Sci. 1969 Feb;58(2):222–225. doi: 10.1002/jps.2600580218. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES